

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lacrampe et al.

Serial No. : Not yet Assigned Art Unit: Not yet Assigned

Filed : Herewith Examiner: Not yet Assigned

For : NOVEL IL-5 INHIBITING 6-AZAUACIL DERIVATIVES MARKING
AND IDENTIFYING RECEPTORS AND IMAGING ORGANS

Mail Stop: Divisional Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months

of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance

under \$1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with \$1.97(e) as set forth below and the fee of
\$180.00 as set forth in \$1.17(p).

☒ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.

☐ If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.

☐ There are no listed references which are not in the
English language.

☒ The relevance of the listed reference which is not in
the English language is as follows: English equivalents for
DE2149645 and EP476439 have been provided (U.S. 3,912,723 and
U.S. 5,256,631 respectively).

☒ Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB 1626-Div2/HBW. This form is submitted in triplicate.

Respectfully submitted,

Hal Bunt Woodrow

Hal B. Woodrow
Reg. No. 32,501
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
DATED: 2/19/04

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	Not yet Assigned
Filing Date	Herewith
First Named Inventor	Lacrampe et al
Group Art Unit	Not yet Assigned
Examiner Name	Not yet Assigned
Attorney Docket Number	JAB-1626-Div2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		3,883,528		Mylari	05/13/1975	
		3,912,723		Miller	10/14/1975	
		4,631,278		Boeckx et al	12/23/1986	
		4,767,760		Boeckx et al	08/30/1998	
		5,256,631		Lindner et al	10/26/1993	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		DE	2149645		Pfizer Inc.	09/14/1972		
		EP	0170316	A2	Janssen Pharmaceutica N.V.	02/05/1986		
		EP	0232932	A1	Janssen Pharmaceutica N.V.	08/19/1987		
		EP	0831088	B1	Takeda Schering-Plough	03/25/1998		
		EP	0476439	A1	Bayer AG	03/25/1992		
		EP	0648760	A3	Takeda Chemical Industries, Ltd.	04/19/1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MISHRA et al., "IL-5 Promotes Eosinophil Trafficking to the Esophagus." <u>The Journal of Immunology</u> , 2002, pages 2464-2469, Vol. 168.	
		BAGGIOLINI, et al., "CC Chemokines in Allergic Inflammation." <u>Immunology Today</u> , 1994, pages 127-133, Vol. 15, No. 3	
		CARR et al., "Expression On Porcine $\gamma\delta$ lymphocytes Of A Phylogenetically Conserved Surface Antigen Previously Restricted In Expression $\gamma\delta$ T Lymphocytes." 1994, pages 36-40, Vol.81.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

[illegible][illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--